Investing.com - Needham downgraded Biogen Inc (NASDAQ: BIIB) on Monday, citing slower-than-expected growth for its ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

And this corruption even extends into the Food and Drug Administration (FDA). Three years ago, Biogen got the FDA to approve its Alzheimer drug Aduhelm, even though there was little proof of its ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Baler, Aurora, Philippines Video Recording Date/Time: November 17, 2024 at 15:35h Super Typhoon Man-Yi, known locally as Pepito, made its second landfall in Dipaculao, Aurora, at 3:20 p.m. on Sunday, ...

Opuviz, which references Regeneron Pharmacueticals’ vision loss inhibitor Eylea, treats wet age-related macular degeneration, ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

risks and uncertainties associated with drug development and commercialization, including OPUVIZ; the potential of Biogen's commercial business and pipeline programs, including BYOOVIZ, BENEPALI, ...

A breakthrough drug, proven to substantially slow the progression of the ... it deserves credit for being flexible enough to ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...